retatrutide benefits clinical trials Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial ESC 2024: Retatrutide improves lipid

Combining a short-acting sympathomimetic with a long-acting peptide hormone receptor agonist creates an imbalanced treatment period and increases the likelihood of adverse effects during the transition when phentermine is discontinued

Ideal candidates are typically adults with a BMI over 27 with a weight-related health condition, or a BMI over 30

To determine whether SLC22A17 is required for LCN2-driven ferroptosis, we transiently silenced endogenous expression of Slc22a17 using siRNA (Fig

To find additional ways to save on GLP-1s, consider discussing your insurance coverage with your doctor

Mar 2021;10(3):1401-1409